| Literature DB >> 24890710 |
H J Jansen1, F J Breeveld, C Stijnis, M P Grobusch.
Abstract
Biological weapons achieve their intended target effects through the infectivity of disease-causing infectious agents. The ability to use biological agents in warfare is prohibited by the Biological and Toxin Weapon Convention. Bioterrorism is defined as the deliberate release of viruses, bacteria or other agents used to cause illness or death in people, but also in animals or plants. It is aimed at creating casualties, terror, societal disruption, or economic loss, inspired by ideological, religious or political beliefs. The success of bioterroristic attempts is defined by the measure of societal disruption and panic, and not necessarily by the sheer number of casualties. Thus, making only a few individuals ill by the use of crude methods may be sufficient, as long as it creates the impact that is aimed for. The assessment of bioterrorism threats and motives have been described before. Biocrime implies the use of a biological agent to kill or make ill a single individual or small group of individuals, motivated by revenge or the desire for monetary gain by extortion, rather than by political, ideological, religious or other beliefs. The likelihood of a successful bioterrorist attack is not very large, given the technical difficulties and constraints. However, even if the number of casualties is likely to be limited, the impact of a bioterrorist attack can still be high. Measures aimed at enhancing diagnostic and therapeutic capabilities and capacities alongside training and education will improve the ability of society to combat 'regular' infectious diseases outbreaks, as well as mitigating the effects of bioterrorist attacks.Entities:
Keywords: Biocrime; biological agents; biological warfare; bioterror; bioterrorism; bioweapons
Mesh:
Substances:
Year: 2014 PMID: 24890710 PMCID: PMC7129974 DOI: 10.1111/1469-0691.12699
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Selected biological agents potentially involved in bioterrorism
| Disease | Agent | Organism persistence | Infective dose | Human‐to‐human transmission | Infectivity | Incubation period | Symptoms | Mortality | Treatment |
|---|---|---|---|---|---|---|---|---|---|
| Anthrax | Spores of Bacillus anthracis | Very stable, spores may be viable for >40 years in soil | 8000–50 000 spores | No | – | 1–6 days | Fatigue, fever, malaise, cough, mild chest discomfort, respiratory distress, shock | High | Ciprofloxacin or doxycycline |
| Brucellosis | Genus Brucella (B. melitensis, B. suis, B. abortus, B. canis) | 6 weeks. In dust to 10 weeks. In soil or water | 10–100 organisms | No | – | 5–60 days | Fever, headache, malaise, chills, sweating, myalgia, arthralgia, depression | 5% if untreated | Doxycycline + rifampicin |
| Glanders | Burkholderia mallei | Very stable | Unknown | Rare but possible | – | 10–14 days | Pulmonary form: cough, chest pain, fever, rigors, sweating, pleuritis | Very high if untreated | Ceftazidime, imipenem, or meropenem. Post‐exposure prophylaxis with co‐trimoxazole |
| Melioidosis | Burkholderia pseudomallei | Very stable | Unknown | Rare but possible | – | 10–14 days | Very high if untreated | ||
| Plague | Yersinia pestis | Up to 1 year in soil, but viable only for 1 h after aerosol release | 100–20 000 organisms | High | Patients contagious for up to 3 days after starting treatment | 1–6 days | High fever, headache, malaise, chest pain, cough, haemoptysis, dyspnoea, stridor, cyanosis | Very high if untreated, <10% with antibiotics | Streptomycin or gentamicin with ciprofloxacin or doxycycline |
| Q‐fever | Coxiella burnetii | Resistant to heat and drying, persists for weeks to months | 1–10 organisms | Rare but possible | – | 7–41 days | Fever, chills, headache, malaise, fatigue, anorexia, weight loss, endocarditis (as presenting symptom of chronic disease) | 1% untreated, chronic form 30–60% | Tetracycline or doxycycline |
| Salmonellosis | Genus Salmonella (S. typhi, S. paratyphi) | Resistant to heat up to 57–60°C | Unknown | Faecal–oral transmission | Up to 4–5 weeks in faeces | 6–48 h | Nausea, vomiting, mucopurulent or bloody diarrhoea, abdominal cramps, headache, maculopapular exanthema | <1% | Supportive care to prevent dehydration. In severe infections fluoroquinolones or third‐generation cephalosporins |
| Shigellosis | Genus Shigella (S. dysenteriae, S. flexneri, S. sonnei and S. boydii) | Mean survival of 2–3 days, up to 17 days in favourable circumstances, several hours on infected hands | 10–100 organisms | Faecal–oral transmission | In acute phase, high excretion in faeces; without antibiotic treatment, up to 4 weeks | 1–7 days | Fever, abdominal cramps, diarrhoea, haemorrhagic colitis | <1% | Usually self‐limiting. In severe infections, trimethoprim–sulphamethoxazole and ciprofloxacin shorten duration of symptoms and excretion in faeces |
| Tularaemia (rabbit fever) | Francisella tularensis ssp. tularensis | Weeks in water, soil, or carcasses, and years in frozen meat | 10–50 organisms | No | – | 1–25 days (mean 3–5 days) | Fever, chills, myalgia, arthralgia, headache, nausea, vomiting, diarrhoea, sore throat | 4–50% mortality without treatment. With treatment, 1% | Streptomycin or gentamicin |
| Smallpox | Variola virus: Variola major | Highly stable for up to 1 year in dust and cloth | 10–100 organisms | Yes, transmission requires close contact | Mostly contagious during first week of rash | 4–19 days (mean 10–12 days) | Severe headache, high fever, extreme prostration, backache, chest and join pains, anxiety, exanthema, maculopapular rash that becomes vesicular | Ordinary‐type smallpox: 30% if unvaccinated; 3% if vaccinated | No antiviral treatment, vaccination immediately or up to 4 days after exposure can reduce mortality |
| Venezuelan equine encephalitis | Alphavirus, (Venezuelan equine encephalitis virus complex) | Unstable in environment | 10–100 organisms | No | – | 2–6 days | Malaise, spiking fevers, rigors, headache, myalgia, nausea, photophobia, vomiting, cough, encephalitis (4% children, <1% adults), diarrhoea, sore throat | <1% | Supportive treatment |
| Botulism | Botulinum toxin produced by Clostridium botulinum | Weeks in non‐moving food or water | LD50 is 0.001 μg/kg for type A (parenteral), 0.003 μg/kg (aerosol) | No | – | 2 h to 10 days (mean 12–72 h) | Acute afebrile, symmetric paralysis descending from the head | Without supportive treatment: high mortality resulting from to respiratory failure | Supportive treatment, trivalent or heptavalent antitoxins |
| Ricin | Derived from beans of castor plant Ricinus communis | Stable until heated above 80°C | LD50 1 mg | No | – | Inhalation 4–8 h (mild symptoms), 18–24 h (severe symptoms) | Inhalation: fever, respiratory distress, cough. Ingestion: gastrointestinal haemorrhage. Both: multiorgan failure | High | Supportive treatment |
| Staphylococcal enterotoxin B | Produced by Staphylococcus aureus | Resistant to freezing, inactivated at 100°C | 0.03 μg/person | No | – | Inhalation 3–12 h, ingestion 4–10 h | Fever, chills, dyspnoea, non‐productive cough, headache, myalgia, retrosternal chest pain | <1% | Supportive treatment |
Trends in bio‐agent cases 1900–1999 (modified from Carus 13)
| Decade | Bioterrorist | Biocriminal | Other/uncertain | Total |
|---|---|---|---|---|
| 1990–1999 | 19 | 40 | 94 | 153 |
| 1980–1989 | 3 | 6 | 0 | 9 |
| 1970–1979 | 3 | 2 | 3 | 8 |
| 1960–1969 | 0 | 1 | 0 | 1 |
| 1950–1959 | 1 | 0 | 0 | 1 |
| 1940–1949 | 1 | 0 | 0 | 1 |
| 1930–1939 | 0 | 3 | 0 | 3 |
| 1920–1929 | 0 | 0 | 0 | 0 |
| 1910–1919 | 0 | 3 | 0 | 3 |
| 1900–1909 | 0 | 1 | 0 | 1 |
| Totals | 7 | 56 | 97 | 180 |